| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Control Delivery System, Inc. |
| 313 Pleasant Street, Watertown, MA 02472 * (617) 926-5000 |
| Business Description | The company designs, develops and manufactures innovative, sustained-release drug delivery products. Our products are designed to treat severe and chronic diseases that have limited or no effective treatment options and represent significant market opportunities. |
|
Filing Information Not yet | |||
| To Trade As | CDSY (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 12/15/2000 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $75,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Deutsch Banc Alex. Brown | Lead Manager | (410) 727-1700 |
| Banc of America Securities LLC | Co-manager | (415) 627-2100 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1995 | 12/31/1996 | 12/31/1997 | 12/31/1998 | 12/31/1999 | 9/30/1999 | 9/30/2000 |
| Revenues | 0.631 | 2.221 | 1.349 | 1.115 | 2.785 | 1.777 | 4.176 |
| Income from Oper. | 0.023 | 0.747 | -0.401 | -0.869 | -0.133 | -0.280 | 0.094 |
| Net Income | 0.030 | 0.748 | -0.394 | -0.866 | -0.094 | -0.251 | 0.401 |
| E.P.S | 0.020 | 0.370 | -0.200 | -0.420 | -0.050 | -0.120 | 0.322 |
| Revenue Growth (%) | 251.98 | -39.26 | -17.35 | 149.776 | 135.00 | ||
| Net Income Growth (%) | 2,393.33 | - | - | - | - | ||
| Oper. Profit Margin (%) | 3.65 | 33.63 | - | - | - | 2.25 | - |
| Net Profit Margin (%) | 4.75 | 33.68 | - | - | - | 9.60 | - |
| Cash Flow - Oper. | 1.23 | 1.02 | 0.45 | ||||
| Cash Flow - Inv. | -0.25 | -0.11 | -0.62 | ||||
| Cash Flow - Fin. | 0.03 | 0.23 | 30.06 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/2000 | Financial Ratios | ||||
| Total Assets | 32.01 | Current Assets | 31.16 | Current Ratio | 10.99 |
| Total Liab. | 34.09 | Current Liab. | 2.84 | Debt Ratio | 106.52% |
| Total Equity | -2.09 | Working Cap. | 28.32 | Debt to Equity Ratio | - |
| Cash | 31.03 | Return on Assets | 1.25% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research, development and commercialization of products, expansion of manufacturing facilities and general corporate purposes including working capital. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Ropes & Gray |
| Bank's Law Firm | Piper & Marbury |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Bausch & Lomb Incorporated | 23.50 | |
| Essex Woodlands Health Ventures | 7.30 | |
| Note: represents ownership of 5% or more prior to the offering. | ||